Trials / Terminated
TerminatedNCT00062699
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
A Phase IV, Prospective, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Survival Benefits of Zemplar Relative to Calcijex in Subjects With Stage V Chronic Kidney Disease on Hemodialysis
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,200 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zemplar (paricalcitol injection) | |
| DRUG | Calcijex |
Timeline
- Start date
- 2003-04-01
- First posted
- 2003-06-13
- Last updated
- 2006-08-02
Locations
60 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00062699. Inclusion in this directory is not an endorsement.